GLP-1 receptor agonists in Parkinson’s disease: a meta-analysis revealing motor benefit and highlighting mood improvement - Report - MDSpire

GLP-1 receptor agonists in Parkinson’s disease: a meta-analysis revealing motor benefit and highlighting mood improvement

  • By

  • Yutong Chen

  • Zhehao Zhang

  • Zheng Liu

  • Tingting Lv

  • Mengfei Ye

  • Junwei Yan

  • Min Zhang

  • July 3, 2026

  • 0 min

Share

Clinical Report: Efficacy of GLP-1 Receptor Agonists in Parkinson's Disease

Overview

This meta-analysis evaluates the efficacy of GLP-1 receptor agonists (GLP-1RAs) in improving motor function in Parkinson's disease patients. The findings indicate improvements in motor function, alongside manageable side effects.

Background

Parkinson's disease (PD) is a major global health issue, with increasing prevalence and significant impacts on quality of life. Current treatments often lead to complications, highlighting the need for novel therapeutic options. GLP-1 receptor agonists, primarily used for type 2 diabetes, have shown potential properties that may benefit PD patients.

Data Highlights

OutcomeEffect Size (SMD)95% CIp-value
Motor function post-treatment-0.21-0.35 to -0.070.003
Motor function follow-up-0.32-0.55 to -0.080.009
Mood post-treatment-0.36-0.58 to -0.140.001
Mood follow-up-0.27-0.48 to -0.060.013
Cognitive function follow-up-0.34-0.50 to -0.18<0.001
Weight lossOR = 3.871.88 to 7.94<0.001
Gastrointestinal disordersOR = 2.852.29 to 3.54<0.001
PD symptom exacerbationOR = 0.600.38 to 0.940.025

Key Findings

  • GLP-1RAs significantly improved motor function in PD patients both post-treatment and at follow-up.
  • Improvements in mood were observed post-treatment.
  • Weight loss and gastrointestinal disorders were more frequent among patients treated with GLP-1RAs.
  • GLP-1RAs were associated with a reduction in PD symptom exacerbation.

Clinical Implications

Clinicians should be aware of the potential for gastrointestinal side effects and weight loss when considering GLP-1RAs for treatment.

Conclusion

GLP-1 receptor agonists demonstrate efficacy in improving motor function in Parkinson's disease.

Related Resources & Content

  1. Frontiers in Endocrinology, 2026 -- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model
  2. Frontiers in Immunology, 2026 -- GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection
  3. Frontiers in Neurology, 2026 -- Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study
  4. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee - PMC
  5. Trial of Lixisenatide in Early Parkinson’s Disease | New England Journal of Medicine
  6. Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized clinical trials - PMC
  7. glaucoma physician — The Impact of GLP-1 Receptor Agonists on Ocular Disease
  8. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee - PMC
  9. Trial of Lixisenatide in Early Parkinson’s Disease | New England Journal of Medicine
  10. Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized clinical trials - PMC

Original Source(s)

GLP-1 receptor agonists in Parkinson’s disease: a meta-analysis revealing motor benefit and highlighting mood improvement

  • by Yutong Chen, Zhehao Zhang, Zheng Liu, Tingting Lv, Mengfei Ye, Junwei Yan, Min Zhang

  • July 3, 2026

Related Content

How we use the neurological pupil index (NPi)

Long-term functional outcomes after unilateral versus bilateral decompressive craniectomy—a single center experience

Risk factors and mediating mechanisms of restless legs syndrome in patients undergoing maintenance hemodialysis: a longitudinal cohort study combined with Mendelian randomization analysis